m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02872)
Name
ABT-510
Synonyms
N-Acetyl-N-methyl-glycyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-argininyl-L-proline N-ethylamide
    Click to Show/Hide
Status
Phase 2
Structure
3D MOL
2D MOL
Formula
C46H83N13O11
InChI
1S/C46H83N13O11/c1-12-18-30(39(64)55-36(26(7)13-2)42(67)53-31(19-16-21-50-46(47)48)45(70)59-22-17-20-32(59)40(65)49-15-4)52-44(69)38(28(9)60)57-43(68)37(27(8)14-3)56-41(66)35(25(5)6)54-33(62)23-51-34(63)24-58(11)29(10)61/h25-28,30-32,35-38,60H,12-24H2,1-11H3,(H,49,65)(H,51,63)(H,52,69)(H,53,67)(H,54,62)(H,55,64)(H,56,66)(H,57,68)(H4,47,48,50)/t26-,27-,28+,30-,31-,32-,35-,36-,37+,38-/m0/s1
InChIKey
RIWLPSIAFBLILR-WVNGMBSFSA-N
PubChem CID
6918562
TTD Drug ID
D0G4MB
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Thrombospondin-1 (THBS1)
Insulin-like growth factor-binding protein 3 (IGFBP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Thrombospondin-1 (THBS1) is a therapeutic target for ABT-510. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of ABT-510 through regulating the expression of Thrombospondin-1 (THBS1). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Thrombospondin-1 (THBS1) is a therapeutic target for ABT-510. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ABT-510 through regulating the expression of Thrombospondin-1 (THBS1). [2], [3]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Thrombospondin-1 (THBS1) is a therapeutic target for ABT-510. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ABT-510 through regulating the expression of Thrombospondin-1 (THBS1). [2], [3]
References
Ref 1 IGFBP3 inhibits angiogenesis through intracellular regulation of THBS1 expression. Am J Cancer Res. 2020 Jun 1;10(6):1728-1744. eCollection 2020.
Ref 2 Clinical pipeline report, company report or official report of Immune-Onc Therapeutics.
Ref 3 METTL14 promotes prostate tumorigenesis by inhibiting THBS1 via an m6A-YTHDF2-dependent mechanism. Cell Death Discov. 2022 Mar 30;8(1):143. doi: 10.1038/s41420-022-00939-0.